## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2022-01-12_Virtual Town Hall 76_fixnames.md
last updated: 2025-01-05 Created QA Sections
link pdf: https://www.fda.gov/media/155886/download?attachment
link youtube: https://youtu.be/otDWtDNNHzY
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Guidance on Laboratory Modifications to Authorized COVID-19 Tests

QA Block 1-1
CLARIFIED QUESTION: Would a premarket submission for over-the-counter COVID-19 tests be submitted as a 510(k), or would this be a de novo?
CLARIFIED ANSWER: The FDA expects the first over-the-counter COVID-19 test submission to be a de novo, with subsequent similar tests submitted as 510(k)s.
VERBATIM QUESTION: Would a premarket submission for over-the-counter COVID-19 tests be submitted as a 510(k), or would this be a de novo?
VERBATIM ANSWER: So we've not yet granted a full authorization for an over-the-counter COVID-19 test. So the first one we would likely expect to be submitted as a de novo, and then once we offer as the first de novo, subsequent similar tests would be 510ks.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Over-the-counter COVID-19 tests, Premarket submission process
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: Can FDA clarify whether modifications made by a laboratory to an emergency use authorized COVID-19 diagnostic test prior to November 15, 2021, to add new specimen types can continue to be used without FDA authorization?
CLARIFIED ANSWER: The FDA allows laboratories to continue using modifications made to an EUA COVID-19 diagnostic test to add new specimen types before November 15, 2021, without further authorization if the new specimen type was previously authorized for a similar technology and properly validated.
VERBATIM QUESTION: Can FDA clarify whether modifications made by a laboratory to an emergency use authorized COVID-19 diagnostic test prior to November 15, 2021, to add new specimen types can continue to be used without FDA authorization?
VERBATIM ANSWER: Yes, as long as the specimen type is one that has been previously authorized for another test for the same technology. This is discussed in Section 4D2 of the updated guidance. And it notes that for modifications made as discussed in previous versions of the guidance, prior to authorized COVID-19 diagnostic test for use with a new specimen type, where the new specimen type has been previously authorized for another test of the same technology, and where the lab has validated the test for the new specimen type, FDA does not intend to object to the continued use-Â­ that's continued now after the November 15 guidance-- of such a modified test without notification to FDA or a new or amended EUA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Laboratory test modifications, Specimen type validation, FDA EUA guidance
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What is the process for submitting validation data for laboratories developing an LDT and needing EUA authorization?
CLARIFIED ANSWER: The process involves submitting a copy, scanned or photocopied, of the CLIA validation records along with a cover letter. These documents should be sent electronically to the FDA templates email box.
VERBATIM QUESTION: What is the process for submitting validation data for laboratories developing an LDT and needing EUA authorization?
VERBATIM ANSWER: I want to make sure that labs know - LDT developers know - just how easy it is to submit their validation data. It can simply be a copy, a scanned copy, a photocopy of their CLIA validation records. That can be your submission. Make that copy. Send it electronically to us at the template box along with a cover letter that says what we're doing. It's as easy as that. There should be really no problem with doing that for all the CLIA-validated tests out there that want to stay on the market.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation submission process, EUA authorization for LDTs
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: Does the FDA require a specific test volume threshold for LDTs seeking EUA authorization?
CLARIFIED ANSWER: The FDA does not require a test volume threshold for LDTs validated before November 15, 2021. Both low-volume and high-volume labs are acceptable without volume metric recommendations.
VERBATIM QUESTION: Does the FDA require a specific test volume threshold for LDTs seeking EUA authorization?
VERBATIM ANSWER: There is no test volume requirement for LDTs that are in this category. So those that have been validated prior to November 15, 2021, there is no volume metric recommendation. Small labs with low- volume tests, they're fine just as well as large labs with high-volume tests. We did this in an effort to not decrease test availability and to allow all the LDTs that have been developed and launched and validated and launched in the US as of that date, which was a long time to take to develop a test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test volume thresholds, LDT EUA authorization, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: What are the acceptable methods for validating diagnostic tests for Omicron-specific performance on antigen tests?
CLARIFIED ANSWER: FDA recommends validating Omicron performance on antigen tests using live patient samples, including banked samples in saline, to confirm test performance. A new clinical study is not required.
VERBATIM QUESTION: What are the acceptable methods for validating diagnostic tests for Omicron-specific performance on antigen tests?
VERBATIM ANSWER: Testing with actual live patient samples, even if banked as long as they're probably in saline, is an option to actually including omicron patients in your clinical study. We're not asking you to do a new clinical study. We just want to know, is the test performing on omicron samples? And there are multiple ways to get to that end.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Diagnostic test validation, Omicron-specific performance, Antigen tests
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: For new submissions involving omicron, what types of clinical data are recommended by the FDA to demonstrate test performance?
CLARIFIED ANSWER: FDA recommends providing clinical data showing test performance on omicron samples, which may include testing with live or banked patient samples. A new clinical study is not required if existing samples can demonstrate performance.
VERBATIM QUESTION: For new submissions involving omicron, what types of clinical data are recommended by the FDA to demonstrate test performance?
VERBATIM ANSWER: Any new EUA requests for antigen tests, we're recommending clinical data with omicron. This can be encompassed within the present policies or covered under the present policies for variant detection. We know that omicron is widespread right now. And if your validation was done before omicron, we really need to know how it performs with omicron, because there is the potential for a decrease in clinical sensitivity. There have been numerous preprints and anecdotal reports showing a potential loss of sensitivity here. The FDA has NIH RADx data that's suggestive of that as well. So in order to speed your process to get this data, please reach out to your FDA reviewer for ways that you can address this as soon as possible. Testing with actual live patient samples, even if banked as long as they're probably in saline, is an option to actually including omicron patients in your clinical study. We're not asking you to do a new clinical study. We just want to know, is the test performing on omicron samples? And there are multiple ways to get to that end.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Omicron variant, Clinical data for EUA, Test performance validation
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: How does the FDA view the use of oropharyngeal or throat swabs in authorized diagnostic tests, especially those used by consumers at home?
CLARIFIED ANSWER: The FDA advises the use of COVID-19 tests strictly as authorized, following the specified sample collection methods. Home antigen tests are only authorized for nasal swabs. While FDA has received unsuccessful saliva submissions and lacks data on throat swabs for at-home use, they are open to receiving more data. Saliva, throat swabs, and other oral specimens differ and may not perform equally well.
VERBATIM QUESTION: How does the FDA view the use of oropharyngeal or throat swabs in authorized diagnostic tests, especially those used by consumers at home?
VERBATIM ANSWER: Now moving to the next topic, there has been a lot of interest in the preprint data showing that saliva and/or other oral swabs or even oropharyngeal swabs may provide earlier detection of omicron than a nasal swab. And there has been discussion of use of, say, throat swabs, otherwise known as oropharyngeal swabs, for OTC tests and other tests, frankly, for which they have not been validated for. The FDA does advise that COVID-19 tests should be used as authorized, including following their instructions for use regarding obtaining the sample for testing. The home antigen tests available today are only authorized for nasal swabs. We have received some saliva submissions. So far, they've been unsuccessful due to performance issues. We do not have any data yet suggesting throat swabs are inaccurate or appropriate method for at-home tests. But we're open to receiving submissions. Of note, that saliva and throat swabs and other swabs within the oral cavity are different types of specimens. And they may not perform equally well. So just because something works, say, for oropharyngeal doesn't mean it will work for saliva or any other sample type within the oropharynx.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Oropharyngeal swabs, At-home testing, FDA guidelines
REVIEW FLAG: False

QA Block 1-9
CLARIFIED QUESTION: What kind of data should accompany submissions involving saliva or throat swabs to demonstrate their effectiveness as sample types for COVID-19 tests?
CLARIFIED ANSWER: FDA advises that tests be used as authorized, but is open to submissions to evaluate saliva or throat swabs. Saliva submissions have faced performance issues, and throat swab data is lacking. FDA stresses that specimen types perform differently, and validation data is crucial.
VERBATIM QUESTION: What kind of data should accompany submissions involving saliva or throat swabs to demonstrate their effectiveness as sample types for COVID-19 tests?
VERBATIM ANSWER: The FDA does advise that COVID-19 tests should be used as authorized, including following their instructions for use regarding obtaining the sample for testing. The home antigen tests available today are only authorized for nasal swabs. We have received some saliva submissions. So far, they've been unsuccessful due to performance issues. We do not have any data yet suggesting throat swabs are inaccurate or appropriate method for at-home tests. But we're open to receiving submissions. Of note, that saliva and throat swabs and other swabs within the oral cavity are different types of specimens. And they may not perform equally well. So just because something works, say, for oropharyngeal doesn't mean it will work for saliva or any other sample type within the oropharynx. So we have authorized many molecular tests for saliva. But we've also seen some poor performance from molecular tests. And then, as I mentioned, antigen tests so far, we've looked at some that have been unsuccessful with saliva as a sample type for reasons unknown and could be worked out. And obviously, we're interested in that saliva as a sample type even for antigen tests if the issues can be worked out. The FDA has authorized OP swabs for some molecular tests but has not authorized them, as I said, for antigen tests. A check of our records, in fact, indicates that we're not aware of any oropharyngeal submissions or throat swab submissions for antigen tests, which the FDA, as I stated, is open to receiving.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva and throat swab data, COVID-19 test validation, FDA submission guidance
REVIEW FLAG: False

QA Block 1-10
CLARIFIED QUESTION: Are there recommended safety measures or data points to address potential risks associated with throat swab self-collection?
CLARIFIED ANSWER: FDA has noted concerns about self-collection of throat swabs due to their complexity and potential risks, such as false results, mechanical injuries, aspiration risks, and equipment not designed for such use. The CDC recommends that throat swabs be collected by trained healthcare providers.
VERBATIM QUESTION: Are there recommended safety measures or data points to address potential risks associated with throat swab self-collection?
VERBATIM ANSWER: The FDA has also noted concerns regarding self-collection of throat swabs, as they have been-- they are more complicated than nasal swab. Nasal swabs were ideal in many ways for home collection, unsupervised self-collection and, in some cases, even in some kids and, if used incorrectly, can cause harm to the patient. Some potential safety concerns may include risk of false negative, false positive results for tests that were not developed or validated for use with oropharyngeal specimens. And then, of course, oropharyngeal and/or saliva or other oral samples types may work better or worse for different variant types. There is evidence that OP swabs or saliva may have been worse for, say, delta than for nasal swab. So a performance may change. And having more options is great. We just like to see some data, including that it's an accurate way to do it and that it's safe. So mechanical injuries to the tonsils or throat from the swab, there are. Obvious patient preference is for nasal swab over getting a throat swab. Throat swabs frequently induce gagging or vomiting, which can lead to an aspiration of gastric contents or oral contents into the lungs, which could cause a pneumonia, which could complicate obviously a SARS-CoV-2 infection or other underlying lung diseases. And pieces as well could break off. They're more fragile. The current swabs aren't necessarily designed for throat swabbing. Some of them may be too short for this. And, of course, the CDC does recommend that throat swabs be collected by a trained health care provider.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Safety of throat swab collection, Self-collection risks, Recommendations for healthcare providers
REVIEW FLAG: False

QA Block 1-11
CLARIFIED QUESTION: Can a genotyping test for SARS-CoV-2 variants meet diagnostic validation requirements by incorporating data from archived samples or genomic sequencing?
CLARIFIED ANSWER: The FDA recommends validating genotyping tests using archived clinical samples or inactivated virus within the clinical matrix, with sequencing-based assays serving as the best comparator to establish the accuracy of the genotyping results.
VERBATIM QUESTION: Can a genotyping test for SARS-CoV-2 variants meet diagnostic validation requirements by incorporating data from archived samples or genomic sequencing?
VERBATIM ANSWER: We will likely recommend establishing a performance of the genotyping test with either archives, clinical samples or inactivated virus within the clinical matrix. And, of course, a sequencing-based assay is probably the best comparator here if it's a good sequencing assay for establishing the, quote, "truth" of the genotyping result.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Genotyping tests, Validation requirements, Archived samples
REVIEW FLAG: False

QA Block 1-12
CLARIFIED QUESTION: What validation plans are recommended for developers implementing a genotyping claim in sequencing-based assays?
CLARIFIED ANSWER: FDA recommends submitting a pre-EUA with a detailed intended use statement and validation plans for sequencing-based genotyping claims. It advises including a diagnostic test to mitigate risks of false results, using clinical validation data for performance assessment, and considering a change protocol for easier updates.
VERBATIM QUESTION: What validation plans are recommended for developers implementing a genotyping claim in sequencing-based assays?
VERBATIM ANSWER: As discussed in our February 2021 guidance on mutations, FDA believes that whole genome sequencing tests may be best suited for genotyping claims due to their ability to detect both known and emerging mutations and variants or otherwise unknown mutations, unknown variants that may come along. If you wish to pursue a genotyping claim, a detailed discussion of your validation proposal is best addressed within the context of a pre-EUA. We recommend that you submit a pre-EUA with a detailed intended use statement and validation plans for establishing performance for all mutations you find and detect. Please note that we've recommended including a diagnostic test in your genotyping test so that risk of false result with the genotyping test can be mitigated. Your genotyping test could be a reflex off of an EUA-authorized test. Or the diagnostic test can be incorporated into detection plus-minus of SARS-CoV-2 can be incorporated into your genotyping test. Without a diagnostic test performed in parallel with your genotyping test, the risk to patient, due to false results, is significant. That makes sense. Typically, this type of significant risk is mitigated by providing data from a clinical validation study using samples from patients infected with virus harboring the mutation of interest with the diagnostic test performed in parallel. The risk to patients is reduced. And therefore, we will likely recommend establishing a performance of the genotyping test with either archives, clinical samples or inactivated virus within the clinical matrix. And, of course, a sequencing-based assay is probably the best comparator here if it's a good sequencing assay for establishing the, quote, "truth" of the genotyping result. Please strongly consider, with any sort of genotyping protocol, whether it be whole genome sequencing and/or a non-sequencing-based genotyping or a limited genotyping sequencing assay, whatever, submitting a change protocol with a request with your submission so that you can more easily and quickly update your assay without FDA review prior to launching that update as long as the pre- authorized conditions for that change protocol are met.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: genotyping claims, validation plans, whole genome sequencing
REVIEW FLAG: False

QA Block 1-13
CLARIFIED QUESTION: What criteria must be satisfied to make pre-authorized updates in genotyping test protocols without FDA pre-review?
CLARIFIED ANSWER: Genotyping test developers can make updates without FDA pre-review if they submit a change protocol with their initial submission and meet pre-authorized conditions, sharing validation data with the FDA after implementation.
VERBATIM QUESTION: What criteria must be satisfied to make pre-authorized updates in genotyping test protocols without FDA pre-review?
VERBATIM ANSWER: Please strongly consider, with any sort of genotyping protocol, whether it be whole genome sequencing and/or a non-sequencing-based genotyping or a limited genotyping sequencing assay, whatever, submitting a change protocol with a request with your submission so that you can more easily and quickly update your assay without FDA review prior to launching that update as long as the pre-authorized conditions for that change protocol are met. We, of course, are likely to want to see that data, review it in case there's any issues. But again, if you follow the pre-authorized change protocol, with the output conditions are met, you just go ahead and make that change, launch it, letting us know and showing us the validation data. You don't have to wait on the FDA to review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Genotyping test updates, FDA pre-review conditions
REVIEW FLAG: False


#### 2. FDA Policy on Laboratory-Test Modifications and EUA Requirements

QA Block 2-1
CLARIFIED QUESTION: What are FDA's expectations for EUA submissions when a modification changes the indication for use of a test?
CLARIFIED ANSWER: FDA expects a new or amended EUA to be issued before offering tests with modifications that change the indication for use, such as adding a new specimen type, a new patient population, or altering analyte-specific reagents.
VERBATIM QUESTION: What are FDA's expectations for EUA submissions when a modification changes the indication for use of a test?
VERBATIM ANSWER: And then changes to the indication for use such as adding a new specimen type or a new patient population, such as asymptomatic individuals, would not fall under the modifications policy and FDA would expect a new or amended EUA be issued prior to such a test being offered. Further changes to the PCR primers or probes, for example, would not fall under this policy since that would involve changing the analyte-specific reagents. And FDA similarly, would expect a new or amended EUA be issued prior to such a test being offered.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission expectations, Test modifications, Indication for use changes
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: What does the FDA consider a high complexity CLIA-certified laboratory in the context of modified tests?
CLARIFIED ANSWER: A high complexity CLIA-certified laboratory is one that modifies an EUA-approved test, validates the modification's performance as equivalent to the original, and limits the test's use within the same laboratory.
VERBATIM QUESTION: What does the FDA consider a high complexity CLIA-certified laboratory in the context of modified tests?
VERBATIM ANSWER: Under the modifications policy in the guidance, when a laboratory modifies an EUA authorized test where the laboratory has validated the modification and confirmed that the performance of the modified test is equivalent to the performance of the authorized test, and use of the test is limited to the high complexity CLIA-certified laboratory in which the modification was made, FDA does not expect such a laboratory to submit an EUA request for modifications that do not change the indication for use set forth in the EUA and also do not change the analyte-specific reagents.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: CLIA-certified laboratories, EUA test modifications
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Are laboratories allowed to state or imply FDA authorization for modified tests offered under the FDA modifications policy?
CLARIFIED ANSWER: Laboratories are not allowed to state or imply FDA authorization for modified tests offered under the FDA modifications policy.
VERBATIM QUESTION: Are laboratories allowed to state or imply FDA authorization for modified tests offered under the FDA modifications policy?
VERBATIM ANSWER: Modified tests offered under this policy are offered without FDA authorization, and they should not include any statements that state or imply that the test is FDA authorized. This is discussed in the guidance, so FDA provided recommendations for transparency for such tests in Section 4.C.3 of the guidance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA modifications policy, laboratory tests, authorization statements
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: What types of modifications to an EUA-authorized test do not require a new EUA, according to the FDA?
CLARIFIED ANSWER: FDA does not require a new EUA for modifications to an authorized test if the modifications are validated, do not change the performance or intended use, are limited to high complexity CLIA-certified labs, and do not involve changes to analyte-specific reagents. Examples include adding new or different extraction kits or instruments.
VERBATIM QUESTION: What types of modifications to an EUA-authorized test do not require a new EUA, according to the FDA?
VERBATIM ANSWER: Under the modifications policy in the guidance, when a laboratory modifies an EUA authorized test where the laboratory has validated the modification and confirmed that the performance of the modified test is equivalent to the performance of the authorized test, and use of the test is limited to the high complexity CLIA-certified laboratory in which the modification was made, FDA does not expect such a laboratory to submit an EUA request for modifications that do not change the indication for use set forth in the EUA and also do not change the analyte-specific reagents. These changes can include the addition of a new or different extraction kits or instruments, since the addition of new or different extraction kits or instruments generally would not change the indication for use. Modified tests offered under this policy are offered without FDA authorization, and they should not include any statements that state or imply that the test is FDA authorized.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA test modification, FDA policy, High complexity CLIA labs
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Does changing PCR primers or probes require a new or amended EUA?
CLARIFIED ANSWER: Yes, changes to PCR primers or probes require a new or amended EUA as they involve changing the analyte-specific reagents.
VERBATIM QUESTION: Does changing PCR primers or probes require a new or amended EUA?
VERBATIM ANSWER: Further changes to the PCR primers or probes, for example, would not fall under this policy since that would involve changing the analyte-specific reagents. And FDA similarly, would expect a new or amended EUA be issued prior to such a test being offered.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: PCR primer/probe modification, EUA requirements, Analyte-specific reagents
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Are modifications involving additional specimen types or patient populations, such as asymptomatic individuals, covered under the FDA modifications policy?
CLARIFIED ANSWER: Modifications like adding a new specimen type or patient population (e.g., asymptomatic individuals) do not fall under the FDA modifications policy, and a new or amended EUA would be needed before offering such a test.
VERBATIM QUESTION: Are modifications involving additional specimen types or patient populations, such as asymptomatic individuals, covered under the FDA modifications policy?
VERBATIM ANSWER: And then changes to the indication for use such as adding a new specimen type or a new patient population, such as asymptomatic individuals, would not fall under the modifications policy and FDA would expect a new or amended EUA be issued prior to such a test being offered.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Modifications policy, EUA requirements, New specimen or population
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What recommendations for transparency does the FDA provide for laboratories offering tests under the modifications policy?
CLARIFIED ANSWER: Laboratories should not state or imply that tests offered under the modifications policy are FDA authorized. Transparency recommendations are detailed in Section 4.C.3 of the guidance.
VERBATIM QUESTION: What recommendations for transparency does the FDA provide for laboratories offering tests under the modifications policy?
VERBATIM ANSWER: Modified tests offered under this policy are offered without FDA authorization, and they should not include any statements that state or imply that the test is FDA authorized. This is discussed in the guidance, so FDA provided recommendations for transparency for such tests in Section 4.C.3 of the guidance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA modifications policy, transparency recommendations, laboratory tests
REVIEW FLAG: False


#### 3. Usability Studies for Mobile App Integration in OTC Tests

QA Block 3-1
CLARIFIED QUESTION: Are usability and clinical studies required to support the addition of a mobile app for an over-the-counter antigen test?
CLARIFIED ANSWER: The FDA recommends including a mobile app in the usability study to evaluate the actual use environment, with participants following the entire workflow using the intended sample, mobile app electronic instructions, and result interpretation.
VERBATIM QUESTION: Are usability and clinical studies required to support the addition of a mobile app for an over-the-counter antigen test?
VERBATIM ANSWER: Yes, if you're considering a mobile app option for your device, we recommend that you include the mobile app as part of your usability study so that you're assessing the actual use environment. The entire workflow should be run by the same participants using the intended sample, and include the mobile app electronic instructions and result interpretation by the user in a way that's most consistent with how the device will be used.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mobile app usability study, over-the-counter antigen tests, clinical study requirements
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What does the FDA mean by assessing the actual use environment in usability studies?
CLARIFIED ANSWER: The FDA defines assessing the actual use environment as including the mobile app in usability studies, simulating the full workflow using the intended sample, incorporating app instructions and result interpretation in a way consistent with real-world use.
VERBATIM QUESTION: What does the FDA mean by assessing the actual use environment in usability studies?
VERBATIM ANSWER: Yes, if you're considering a mobile app option for your device, we recommend that you include the mobile app as part of your usability study so that you're assessing the actual use environment. The entire workflow should be run by the same participants using the intended sample, and include the mobile app electronic instructions and result interpretation by the user in a way that's most consistent with how the device will be used.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability studies, actual use environment, mobile app integration
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Should the electronic instructions and result interpretation of the mobile app be part of the usability study?
CLARIFIED ANSWER: The FDA recommends including the mobile app's electronic instructions and result interpretation as part of the usability study to assess the actual use environment.
VERBATIM QUESTION: Should the electronic instructions and result interpretation of the mobile app be part of the usability study?
VERBATIM ANSWER: Yes, if you're considering a mobile app option for your device, we recommend that you include the mobile app as part of your usability study so that you're assessing the actual use environment. The entire workflow should be run by the same participants using the intended sample, and include the mobile app electronic instructions and result interpretation by the user in a way that's most consistent with how the device will be used.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Mobile app usability studies, Electronic instructions, Result interpretation
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: How should developers handle usability testing for the entire workflow of a mobile app in an over-the-counter antigen test?
CLARIFIED ANSWER: Developers should include the mobile app in usability studies, ensuring the workflow is assessed by the same participants using the intended sample. This includes electronic instructions and result interpretation aligned with real-use scenarios.
VERBATIM QUESTION: How should developers handle usability testing for the entire workflow of a mobile app in an over-the-counter antigen test?
VERBATIM ANSWER: Yes, if you're considering a mobile app option for your device, we recommend that you include the mobile app as part of your usability study so that you're assessing the actual use environment. The entire workflow should be run by the same participants using the intended sample, and include the mobile app electronic instructions and result interpretation by the user in a way that's most consistent with how the device will be used.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability testing, mobile app integration, over-the-counter antigen tests
REVIEW FLAG: False


#### 4. FDA's Priority Review for Serology Test Authorization

QA Block 4-2
CLARIFIED QUESTION: What criteria does the FDA use to prioritize review of lab-based and point-of-care serology tests?
CLARIFIED ANSWER: The FDA prioritizes review of serology tests that are high-throughput, measure antibody titers quantitatively, detect neutralizing antibodies, and are from developers able to scale up manufacturing post-authorization.
VERBATIM QUESTION: What criteria does the FDA use to prioritize review of lab-based and point-of-care serology tests?
VERBATIM ANSWER: So as stated in the revised guidance issued November 15, we do intend to prioritize review of lab-based and point-of-care serology tests that are high throughput, intended for the quantitative measurement of antibody titers, or the quantitative detection of neutralizing antibodies from developers who have indicated the ability to scale up manufacturing capacity shortly after authorization.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serology test prioritization, FDA guidance, Manufacturing capacity
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the ability to scale up manufacturing capacity influence the FDA's prioritization decisions for serology test reviews?
CLARIFIED ANSWER: The FDA prioritizes lab-based and point-of-care serology tests that are high throughput, measure antibody titers, or detect neutralizing antibodies, especially if developers can scale up manufacturing after authorization.
VERBATIM QUESTION: Does the ability to scale up manufacturing capacity influence the FDA's prioritization decisions for serology test reviews?
VERBATIM ANSWER: We do intend to prioritize review of lab-based and point-of-care serology tests that are high throughput, intended for the quantitative measurement of antibody titers, or the quantitative detection of neutralizing antibodies from developers who have indicated the ability to scale up manufacturing capacity shortly after authorization.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: prioritization criteria, serology tests, manufacturing capacity
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Are there specific requirements for quantitative measurement of antibody titers when reviewing serology tests?
CLARIFIED ANSWER: FDA prioritizes review of lab-based and point-of-care serology tests that are high throughput, can quantitatively measure antibody titers, or detect neutralizing antibodies, provided the developers can scale manufacturing post-authorization.
VERBATIM QUESTION: Are there specific requirements for quantitative measurement of antibody titers when reviewing serology tests?
VERBATIM ANSWER: As stated in the revised guidance issued November 15, we do intend to prioritize review of lab-based and point-of-care serology tests that are high throughput, intended for the quantitative measurement of antibody titers, or the quantitative detection of neutralizing antibodies from developers who have indicated the ability to scale up manufacturing capacity shortly after authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: quantitative antibody titers, serology tests, FDA review priorities
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What are the prioritization considerations for tests detecting neutralizing antibodies?
CLARIFIED ANSWER: FDA will prioritize lab-based and point-of-care serology tests that are high throughput, intended for quantitative measurement of antibody titers or neutralizing antibodies, and from developers capable of scaling up manufacturing shortly after authorization.
VERBATIM QUESTION: What are the prioritization considerations for tests detecting neutralizing antibodies?
VERBATIM ANSWER: So as stated in the revised guidance issued November 15, we do intend to prioritize review of lab-based and point-of-care serology tests that are high throughput, intended for the quantitative measurement of antibody titers, or the quantitative detection of neutralizing antibodies from developers who have indicated the ability to scale up manufacturing capacity shortly after authorization.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: neutralizing antibodies, serology test prioritization, FDA guidance
REVIEW FLAG: False


#### 5. FDA Recommendations for Over-the-Counter Test Patient Enrollment

QA Block 5-1
CLARIFIED QUESTION: Can FDA clarify the clinical study patient enrollment recommendations to support an over-the-counter test?
CLARIFIED ANSWER: FDA recommends including both symptomatic and asymptomatic data for over-the-counter tests, separately and combined. At least 20 symptomatic and 10 asymptomatic individuals should be included. Asymptomatic individuals should be symptom-free for at least 2 weeks or 2 weeks post-positive test. Those suspected of COVID-19 should be excluded as asymptomatic. FDA requires screening and documentation of patient status, and full data on exposures, symptoms, and days since onset for symptomatic individuals. Performance data should be stratified accordingly.
VERBATIM QUESTION: Can FDA clarify the clinical study patient enrollment recommendations to support an over-the-counter test?
VERBATIM ANSWER: Yeah, so we recommend that you present the symptomatic and asymptomatic data for over-the-counter tests both separately and combined. We generally would expect at least 20 symptomatic individuals, and 10 asymptomatic individuals at the time of authorization. And this is discussed in the antigen and molecular home-use template. There's also information in both the molecular and antigen diagnostic test templates about the definition of asymptomatic individuals, which generally would be someone who's free of symptoms for at least two weeks prior to enrollment and testing. Or if they've previously tested positive, at least two weeks from the time of the last positive test prior to enrollment and testing. And we also would generally expect asymptomatic individuals who are suspected of COVID-19 such as with a known exposure be excluded from consideration as an asymptomatic individual for this context. And then as part of the clinical study protocol and data, we would like to see documentation of how you screened and confirmed that all enrolled individuals were asymptomatic and consistent with your proposed intended use. So in the EUA request, we'd like to see all of the elements of the clinical study provided including known exposures, symptoms, and days since symptom onset for each symptomatic individual included in the clinical validation study. And then we recommend that you stratify the performance data for symptomatic only, asymptomatic only, and then an overall combined analysis.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: clinical study enrollment, over-the-counter tests, asymptomatic and symptomatic data
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What are the requirements for separating and combining symptomatic and asymptomatic data for over-the-counter tests?
CLARIFIED ANSWER: FDA recommends presenting symptomatic and asymptomatic data both separately and combined. They generally require at least 20 symptomatic and 10 asymptomatic individuals for authorization, with specific definitions for asymptomatic individuals provided in diagnostic test templates. Documentation should confirm if individuals are asymptomatic and aligned with the intended use. Performance data should be stratified for symptomatic-only, asymptomatic-only, and combined groups.
VERBATIM QUESTION: What are the requirements for separating and combining symptomatic and asymptomatic data for over-the-counter tests?
VERBATIM ANSWER: Yeah, so we recommend that you present the symptomatic and asymptomatic data for over-the-counter tests both separately and combined. We generally would expect at least 20 symptomatic individuals, and 10 asymptomatic individuals at the time of authorization. And this is discussed in the antigen and molecular home-use template. There's also information in both the molecular and antigen diagnostic test templates about the definition of asymptomatic individuals, which generally would be someone who's free of symptoms for at least two weeks prior to enrollment and testing. Or if they've previously tested positive, at least two weeks from the time of the last positive test prior to enrollment and testing. And we also would generally expect asymptomatic individuals who are suspected of COVID-19 such as with a known exposure be excluded from consideration as an asymptomatic individual for this context. And then as part of the clinical study protocol and data, we would like to see documentation of how you screened and confirmed that all enrolled individuals were asymptomatic and consistent with your proposed intended use. So in the EUA request, we'd like to see all of the elements of the clinical study provided including known exposures, symptoms, and days since symptom onset for each symptomatic individual included in the clinical validation study. And then we recommend that you stratify the performance data for symptomatic only, asymptomatic only, and then an overall combined analysis.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Symptomatic vs asymptomatic data, OTC diagnostic tests, Clinical study protocols
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: How many asymptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
CLARIFIED ANSWER: FDA generally expects at least 10 asymptomatic individuals in a clinical study for over-the-counter test authorization.
VERBATIM QUESTION: How many asymptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
VERBATIM ANSWER: We generally would expect at least 20 symptomatic individuals, and 10 asymptomatic individuals at the time of authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: asymptomatic individuals, clinical study, test authorization
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: What is the FDA definition of 'asymptomatic individuals' for clinical studies?
CLARIFIED ANSWER: The FDA defines 'asymptomatic individuals' as those free of symptoms for at least two weeks prior to enrollment and testing, or for those previously positive, at least two weeks since the last positive test. Individuals suspected of COVID-19 due to known exposure are excluded from being considered asymptomatic.
VERBATIM QUESTION: What is the FDA definition of 'asymptomatic individuals' for clinical studies?
VERBATIM ANSWER: There's also information in both the molecular and antigen diagnostic test templates about the definition of asymptomatic individuals, which generally would be someone who's free of symptoms for at least two weeks prior to enrollment and testing. Or if they've previously tested positive, at least two weeks from the time of the last positive test prior to enrollment and testing. And we also would generally expect asymptomatic individuals who are suspected of COVID-19 such as with a known exposure be excluded from consideration as an asymptomatic individual for this context.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA definition of asymptomatic, Clinical study criteria
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: Should individuals with known COVID-19 exposure be excluded from the asymptomatic category during clinical studies?
CLARIFIED ANSWER: FDA generally expects individuals with a known COVID-19 exposure to be excluded from the asymptomatic category during clinical studies.
VERBATIM QUESTION: Should individuals with known COVID-19 exposure be excluded from the asymptomatic category during clinical studies?
VERBATIM ANSWER: We also would generally expect asymptomatic individuals who are suspected of COVID-19 such as with a known exposure be excluded from consideration as an asymptomatic individual for this context.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID-19 exposure, asymptomatic classification, clinical studies
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What documentation is required to confirm enrolled individuals meet the asymptomatic criteria for the clinical study?
CLARIFIED ANSWER: FDA requires documentation on how enrolled individuals were screened and confirmed to meet the asymptomatic criteria and proposed study use.
VERBATIM QUESTION: What documentation is required to confirm enrolled individuals meet the asymptomatic criteria for the clinical study?
VERBATIM ANSWER: And then as part of the clinical study protocol and data, we would like to see documentation of how you screened and confirmed that all enrolled individuals were asymptomatic and consistent with your proposed intended use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: asymptomatic criteria, clinical study documentation, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: What specific clinical study information should be submitted with the EUA request for over-the-counter tests?
CLARIFIED ANSWER: FDA recommends submitting symptomatic and asymptomatic performance data separately and combined, including at least 20 symptomatic and 10 asymptomatic individuals. Include details on exposures, symptoms, days since symptom onset, and how asymptomatic status was confirmed, consistent with templates.
VERBATIM QUESTION: What specific clinical study information should be submitted with the EUA request for over-the-counter tests?
VERBATIM ANSWER: We recommend that you present the symptomatic and asymptomatic data for over-the-counter tests both separately and combined. We generally would expect at least 20 symptomatic individuals, and 10 asymptomatic individuals at the time of authorization. And this is discussed in the antigen and molecular home-use template. There's also information in both the molecular and antigen diagnostic test templates about the definition of asymptomatic individuals, which generally would be someone who's free of symptoms for at least two weeks prior to enrollment and testing. Or if they've previously tested positive, at least two weeks from the time of the last positive test prior to enrollment and testing. And we also would generally expect asymptomatic individuals who are suspected of COVID-19 such as with a known exposure be excluded from consideration as an asymptomatic individual for this context. And then as part of the clinical study protocol and data, we would like to see documentation of how you screened and confirmed that all enrolled individuals were asymptomatic and consistent with your proposed intended use. So in the EUA request, we'd like to see all of the elements of the clinical study provided including known exposures, symptoms, and days since symptom onset for each symptomatic individual included in the clinical validation study. And then we recommend that you stratify the performance data for symptomatic only, asymptomatic only, and then an overall combined analysis.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA submission requirements, Over-the-counter test validation, Symptomatic and asymptomatic data
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: What details must be included for symptomatic individuals in the clinical validation study?
CLARIFIED ANSWER: For symptomatic individuals in the clinical validation study, the FDA requires documentation on known exposures, symptoms, and days since symptom onset in the EUA request.
VERBATIM QUESTION: What details must be included for symptomatic individuals in the clinical validation study?
VERBATIM ANSWER: So in the EUA request, we'd like to see all of the elements of the clinical study provided including known exposures, symptoms, and days since symptom onset for each symptomatic individual included in the clinical validation study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: symptomatic individual data, clinical validation, EUA request
REVIEW FLAG: False

QA Block 5-10
CLARIFIED QUESTION: How should performance data be stratified for clinical validation of an over-the-counter test?
CLARIFIED ANSWER: FDA recommends stratifying performance data separately for symptomatic individuals, asymptomatic individuals, and with a combined overall analysis for clinical validation of an over-the-counter test.
VERBATIM QUESTION: How should performance data be stratified for clinical validation of an over-the-counter test?
VERBATIM ANSWER: We recommend that you stratify the performance data for symptomatic only, asymptomatic only, and then an overall combined analysis.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: data stratification, OTC test validation
REVIEW FLAG: False


#### 6. FDA Guidance on Antigen Test Weekly Serial Screening

QA Block 6-1
CLARIFIED QUESTION: What is FDA's position on serial antigen testing once per week?
CLARIFIED ANSWER: The FDA has not observed performance data supporting weekly antigen testing intervals. To consider such an interval, developers must provide supporting data and submit a study design proposal. Most antigen test kits authorized for screening asymptomatic individuals are designed for serial testing over three days with 24 to 48 hours between tests.
VERBATIM QUESTION: What is FDA's position on serial antigen testing once per week?
VERBATIM ANSWER: So at this time we have not seen performance data to support a weekly testing interval for antigen tests. In order to increase the serial testing interval to weekly for an antigen test, we would want to see data supporting that time interval. And we suggest that developers interested in pursuing this submit a proposed study design for discussion. Generally, we recommend that COVID-19 tests authorized for serial screening should be used as authorized including following the authorized instructions for use regarding repeat testing within an indicated time frame for asymptomatic individuals. And it's important to note that most antigen test kits that are authorized for screening asymptomatic individuals are authorized for serial screening typically over three days with at least 24 hours, and no more than 48 hours between tests.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial antigen testing, weekly testing intervals, FDA guidance on COVID-19 tests
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: What type of performance data is required to support a proposal for extending the serial testing interval to weekly for antigen tests?
CLARIFIED ANSWER: The FDA requires data supporting the weekly interval for serial testing of antigen tests and advises developers to submit proposed study designs for discussion. Existing antigen tests are mostly authorized for serial screening every 24-48 hours over three days.
VERBATIM QUESTION: What type of performance data is required to support a proposal for extending the serial testing interval to weekly for antigen tests?
VERBATIM ANSWER: So at this time we have not seen performance data to support a weekly testing interval for antigen tests. In order to increase the serial testing interval to weekly for an antigen test, we would want to see data supporting that time interval. And we suggest that developers interested in pursuing this submit a proposed study design for discussion. Generally, we recommend that COVID-19 tests authorized for serial screening should be used as authorized including following the authorized instructions for use regarding repeat testing within an indicated time frame for asymptomatic individuals. And it's important to note that most antigen test kits that are authorized for screening asymptomatic individuals are authorized for serial screening typically over three days with at least 24 hours, and no more than 48 hours between tests.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial antigen testing, performance data, COVID-19 testing intervals
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What process should developers follow to submit a proposed study design for extending the serial testing interval for antigen tests?
CLARIFIED ANSWER: To extend the serial testing interval for antigen tests to weekly, developers should submit a proposed study design for FDA discussion and provide data supporting the extended interval.
VERBATIM QUESTION: What process should developers follow to submit a proposed study design for extending the serial testing interval for antigen tests?
VERBATIM ANSWER: In order to increase the serial testing interval to weekly for an antigen test, we would want to see data supporting that time interval. And we suggest that developers interested in pursuing this submit a proposed study design for discussion.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: serial testing interval, antigen test study submission, developer guidance
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What are the specific authorized instructions for use around repeat testing within indicated time frames for antigen tests?
CLARIFIED ANSWER: The FDA advises that authorized COVID-19 antigen tests for serial screening should be used according to their authorized instructions. Most such tests are authorized for serial screening over three days with at least 24 and no more than 48 hours between tests.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Generally, we recommend that COVID-19 tests authorized for serial screening should be used as authorized including following the authorized instructions for use regarding repeat testing within an indicated time frame for asymptomatic individuals. And it's important to note that most antigen test kits that are authorized for screening asymptomatic individuals are authorized for serial screening typically over three days with at least 24 hours, and no more than 48 hours between tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Authorized antigen test instructions, Serial testing time frames
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: When submitting new data, do developers need to align with current authorization timelines for serial testing (e.g., three days with 24-48 hours between tests)?
CLARIFIED ANSWER: FDA recommends that tests authorized for serial screening be used as per their existing authorization, which typically involves serial testing over three days with intervals of 24-48 hours between tests for asymptomatic individuals.
VERBATIM QUESTION: When submitting new data, do developers need to align with current authorization timelines for serial testing (e.g., three days with 24-48 hours between tests)?
VERBATIM ANSWER: Generally, we recommend that COVID-19 tests authorized for serial screening should be used as authorized including following the authorized instructions for use regarding repeat testing within an indicated time frame for asymptomatic individuals. And it's important to note that most antigen test kits that are authorized for screening asymptomatic individuals are authorized for serial screening typically over three days with at least 24 hours, and no more than 48 hours between tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Serial testing requirements, Authorization timelines
REVIEW FLAG: False


#### 7. FDA Guidance and Transition Plan Implementation Discussion

QA Block 7-1
CLARIFIED QUESTION: Do you have any clarification on how the transition from the emergency use authorization to regular use will be implemented?
CLARIFIED ANSWER: The FDA stated that the guidance on the transition is still draft guidance and it is premature to finalize plans. They encourage submitting comments by March 23, 2022, which will be reviewed before finalizing the plans.
VERBATIM QUESTION: Do you have any clarification on how the transition from the emergency use authorization to regular use will be implemented?
VERBATIM ANSWER: So those guidances were recently issued, but it is premature to say what the final plan will be. The guidance was issued as a draft guidance and we are encouraging everyone to submit comments to the docket including with respect to the specific questions that were submitted for this Town Hall, as well as how to assure that COVID-19 tests are accurate and reliable. When the comment period closes on March 23, 2022, this year, we will review all the comments received and take them into consideration as we finalize our plans.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition from EUA to regular use, FDA guidance, Public comment period
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What specific elements should be addressed in comments submitted to the draft Transition Plan guidance docket?
CLARIFIED ANSWER: The FDA encourages comments on the draft guidance docket regarding specific questions from the Town Hall and ensuring the accuracy and reliability of COVID-19 tests before the deadline of March 23, 2022.
VERBATIM QUESTION: What specific elements should be addressed in comments submitted to the draft Transition Plan guidance docket?
VERBATIM ANSWER: The guidance was issued as a draft guidance and we are encouraging everyone to submit comments to the docket including with respect to the specific questions that were submitted for this Town Hall, as well as how to assure that COVID-19 tests are accurate and reliable. When the comment period closes on March 23, 2022, this year, we will review all the comments received and take them into consideration as we finalize our plans.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition Plan guidance, Comment submission, COVID-19 test reliability
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What measures will the FDA use to ensure COVID-19 tests remain accurate and reliable during the post-emergency transition?
CLARIFIED ANSWER: FDA issued draft Transition Plan guidance and will use public comments submitted by March 23, 2022, to finalize plans, including measures ensuring COVID-19 test accuracy and reliability.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So those guidances were recently issued, but it is premature to say what the final plan will be. The guidance was issued as a draft guidance and we are encouraging everyone to submit comments to the docket including with respect to the specific questions that were submitted for this Town Hall, as well as how to assure that COVID-19 tests are accurate and reliable. When the comment period closes on March 23, 2022, this year, we will review all the comments received and take them into consideration as we finalize our plans.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition plan guidance, Accuracy and reliability of COVID-19 tests, Public comments process
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: Are there specific instructions on how to submit a CLIA validation to the FDA for LDTs validated prior to November 15, 2021?
CLARIFIED ANSWER: For LDTs validated prior to November 15, 2021, the FDA requires submission of a CLIA validation (photocopy or scanned copy) with a cover letter to the template email address by January 14, 2022. These LDTs can remain on the market during the review process.
VERBATIM QUESTION: Are there specific instructions on how to submit a CLIA validation to the FDA for LDTs validated prior to November 15, 2021?
VERBATIM ANSWER: There is no volume minimum for these LDTs. We are not interested in pulling LDTs off the market that were validated prior to November 15th. It doesn't matter the volume. And the submission is very easy, just send us a copy of your CLIA validation. It could be photocopy, scanned copy. Send it to the template email address with a cover letter. That will suffice for you to get your data into us as long as it's in by this Friday, January 14, 2022. And for you to stay on the market, you don't need a pause while we review. You continue to meet the pandemic needs with your LDT while we review it. If we have questions, we'll reach back out and ask you, and work with you if there's any issue.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA validation submission, LDTs staying on market, FDA review process
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: How will the FDA handle issues or concerns with LDTs submitted under the guidance for the January 14 deadline?
CLARIFIED ANSWER: The FDA requires LDTs to submit CLIA validation by January 14, 2022, to stay on the market during review. FDA will not remove validated tests and will address any concerns through communication.
VERBATIM QUESTION: How will the FDA handle issues or concerns with LDTs submitted under the guidance for the January 14 deadline?
VERBATIM ANSWER: There is no volume minimum for these LDTs. We are not interested in pulling LDTs off the market that were validated prior to November 15th. It doesn't matter the volume. And the submission is very easy, just send us a copy of your CLIA validation. It could be photocopy, scanned copy. Send it to the template email address with a cover letter. That will suffice for you to get your data into us as long as it's in by this Friday, January 14, 2022. And for you to stay on the market, you don't need a pause while we review. You continue to meet the pandemic needs with your LDT while we review it. If we have questions, we'll reach back out and ask you, and work with you if there's any issue.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT submission process, CLIA validation, FDA review process
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Is there a requirement to pause LDT testing during FDA review after the submission for the January 14 deadline?
CLARIFIED ANSWER: There is no requirement to pause LDT testing during FDA review after submission for the January 14 deadline. Tests can remain on the market and meet pandemic needs.
VERBATIM QUESTION: Is there a requirement to pause LDT testing during FDA review after the submission for the January 14 deadline?
VERBATIM ANSWER: And for you to stay on the market, you don't need a pause while we review. You continue to meet the pandemic needs with your LDT while we review it.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT testing requirements, FDA review process, January 14 submission deadline
REVIEW FLAG: False


#### 8. Saliva vs. NP Swabs: Validity as PCR Comparator

QA Block 8-1
CLARIFIED QUESTION: Would the FDA consider saliva as a comparator test for COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA continues to consider the NP swab the gold standard for respiratory virus diagnostics, including COVID-19, despite its challenges during the pandemic. Saliva tests have shown issues in molecular diagnostics, so NP swabs remain the comparator sample type. However, discordant analyses involving saliva can be considered with proper study design and through discussion in a Pre-EUA submission.
VERBATIM QUESTION: Would the FDA consider saliva as a comparator test for COVID-19 diagnostics?
VERBATIM ANSWER: Thanks, Wenli. Yes, I understand your question, and I understand your concern. For respiratory viruses, I think most people still recognize the NP swab as the gold standard. It has been problematic to use in this pandemic when people need to be tested so often, but for validating a new test, it does remain the gold standard. And we have seen issues with saliva for molecular tests. So that will still be the comparator sample type. You did bring up what can you do if you have discordance, particularly if the antigen test is positive and the NP swap should be negative. Those discordances can happen both directions. And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use. So that is the way that we've been handling these kind of potential discordances for a long time, not just under this pandemic. It is a tried and true method of examining this in an unbiased way. So with this concern, I would discuss it with your primary reviewer, or if you are going to submit a Pre-EUA, ask it in the Pre-EUA submission, along with your study design and your discordant resolution design. OK? All right, thank you.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva as comparator, NP swab as gold standard, Discordant analysis
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Can both NP and saliva samples be used for RT-PCR and compared with antigen test results?
CLARIFIED ANSWER: The FDA considers NP swabs as the gold standard for respiratory virus detection, including RT-PCR validation. While saliva can be used for antigen tests or discordant analysis, data should align with defined criteria to evaluate test performance. Submit concerns through a primary reviewer or Pre-EUA submission.
VERBATIM QUESTION: Can both NP and saliva samples be used for RT-PCR and compared with antigen test results?
VERBATIM ANSWER: Thanks, Wenli. Yes, I understand your question, and I understand your concern. For respiratory viruses, I think most people still recognize the NP swab as the gold standard. It has been problematic to use in this pandemic when people need to be tested so often, but for validating a new test, it does remain the gold standard. And we have seen issues with saliva for molecular tests. So that will still be the comparator sample type. You did bring up what can you do if you have discordance, particularly if the antigen test is positive and the NP swap should be negative. Those discordances can happen both directions. And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use. So that is the way that we've been handling these kind of potential discordances for a long time, not just under this pandemic. It is a tried and true method of examining this in an unbiased way. So with this concern, I would discuss it with your primary reviewer, or if you are going to submit a Pre-EUA, ask it in the Pre-EUA submission, along with your study design and your discordant resolution design. OK? All right, thank you.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator sample types, RT-PCR validation, Discordant analysis
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What considerations should be taken into account for handling discordant test results involving antigen tests and NP swabs?
CLARIFIED ANSWER: FDA recommends performing unbiased discordant analysis using a comparative battery of tests for adjudication or annotating performance tables to address discrepancies like false positives. Consult with your reviewer or Pre-EUA submission for further guidance.
VERBATIM QUESTION: What considerations should be taken into account for handling discordant test results involving antigen tests and NP swabs?
VERBATIM ANSWER: You did bring up what can you do if you have discordance, particularly if the antigen test is positive and the NP swap should be negative. Those discordances can happen both directions. And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use. So that is the way that we've been handling these kind of potential discordances for a long time, not just under this pandemic. It is a tried and true method of examining this in an unbiased way. So with this concern, I would discuss it with your primary reviewer, or if you are going to submit a Pre-EUA, ask it in the Pre-EUA submission, along with your study design and your discordant resolution design.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Discordant test results, Antigen vs NP swab, FDA guidance
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: How can discordant analysis inform positive percent agreement (PPA) or negative percent agreement (NPA) during validation?
CLARIFIED ANSWER: Discordant analysis can inform PPA or NPA by using a comparative battery of tests to resolve discrepancies and ensure unbiased analysis of results. This can involve up-front analysis or focused assessments of discordant samples, which could be annotated in performance tables and included in test instructions.
VERBATIM QUESTION: How can discordant analysis inform positive percent agreement (PPA) or negative percent agreement (NPA) during validation?
VERBATIM ANSWER: You did bring up what can you do if you have discordance, particularly if the antigen test is positive and the NP swap should be negative. Those discordances can happen both directions. And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Discordant analysis, Test validation, PPA/NPA methodology
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Is it acceptable to focus on properly conducted discordant samples for performance analysis, and how should this be presented in performance tables?
CLARIFIED ANSWER: FDA allows properly conducted discordant analysis for performance evaluation, using unbiased comparative tests. Results can inform metrics like PPA or NPA and be annotated in performance tables, with discordances detailed in usage instructions.
VERBATIM QUESTION: Is it acceptable to focus on properly conducted discordant samples for performance analysis, and how should this be presented in performance tables?
VERBATIM ANSWER: And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use. So that is the way that we've been handling these kind of potential discordances for a long time, not just under this pandemic. It is a tried and true method of examining this in an unbiased way.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: discordant sample analysis, performance tables, antigen test evaluation
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: Can a saliva test confirmed as SARS-CoV-2 positive be used as evidence to address discordances observed with NP swabs?
CLARIFIED ANSWER: The FDA recognizes NP swabs as the gold standard for respiratory viruses but acknowledges that saliva tests can be used in an unbiased discordant analysis if confirmed to be SARS-CoV-2 positive. Such findings can be incorporated into performance data and instructions for use, subject to proper concordant or discordant resolution methodology.
VERBATIM QUESTION: Can a saliva test confirmed as SARS-CoV-2 positive be used as evidence to address discordances observed with NP swabs?
VERBATIM ANSWER: Yes, I understand your question, and I understand your concern. For respiratory viruses, I think most people still recognize the NP swab as the gold standard. It has been problematic to use in this pandemic when people need to be tested so often, but for validating a new test, it does remain the gold standard. And we have seen issues with saliva for molecular tests. So that will still be the comparator sample type. You did bring up what can you do if you have discordance, particularly if the antigen test is positive and the NP swap should be negative. Those discordances can happen both directions. And there are ways to do discordant analysis up front on every sample, which can-- by using the right comparative battery of tests in order to adjudicate any discordances, if the proper concordant analysis testing is done on every sample in an unbiased fashion. That can be used to inform your PPA or NPA. Otherwise, if it's more focused on just the discordant samples done properly as well, we have the ability to annotate the 2 by 2 tables that list your performance characteristics, i.e., if the antigen test has what looks like false positives, compared to the NP swab, but you have a saliva test that is confirmed to be SARS-CoV-2, that can be a component of discordant analysis that can be placed into your instructions for use. So that is the way that we've been handling these kind of potential discordances for a long time, not just under this pandemic. It is a tried and true method of examining this in an unbiased way. So with this concern, I would discuss it with your primary reviewer, or if you are going to submit a Pre-EUA, ask it in the Pre-EUA submission, along with your study design and your discordant resolution design.
SPEAKER QUESTION: Wenli Zhou
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva test as evidence, NP swabs, discordant analysis
REVIEW FLAG: False

QA Block 8-7
CLARIFIED QUESTION: What details should be included in a Pre-EUA submission about discordant resolution design and study design for COVID-19 diagnostics?
CLARIFIED ANSWER: Include both study design details and discordant resolution design in the Pre-EUA submission. Discuss concerns with your primary reviewer if needed.
VERBATIM QUESTION: What details should be included in a Pre-EUA submission about discordant resolution design and study design for COVID-19 diagnostics?
VERBATIM ANSWER: So with this concern, I would discuss it with your primary reviewer, or if you are going to submit a Pre-EUA, ask it in the Pre-EUA submission, along with your study design and your discordant resolution design.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Pre-EUA submission, Discordant resolution design, Study design
REVIEW FLAG: False


#### 9. Usability Studies for Hybrid Versus Actual Device Testing

QA Block 9-2
CLARIFIED QUESTION: Can a developer use a hybrid model with screenshots and a keypad instead of an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?
CLARIFIED ANSWER: The FDA generally expects the usability study to reflect how the final product will be used, emphasizing the importance of aligning the study with the intended interface and use of the product.
VERBATIM QUESTION: Can a developer use a hybrid model with screenshots and a keypad instead of an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?
VERBATIM ANSWER: So we generally want to see the usability study performed as close as possible to how the test will be performed. So it really depends on what you're intending to use as a final product and how a user will interface with it. We would want to see the usability study address it that way.
SPEAKER QUESTION: Karl Enters
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability study for OTC tests, hybrid model, device interface
REVIEW FLAG: False


#### 10. Clarifying FDA Response Requirements for Distributors and Labs

QA Block 10-1
CLARIFIED QUESTION: Do distributors and labs have to wait for a response from the FDA before they can begin their activity after notifying the agency?
CLARIFIED ANSWER: Distributors must wait for FDA approval after notifying the agency before they can begin their activities, and labs may require review based on their authorization language.
VERBATIM QUESTION: Do distributors and labs have to wait for a response from the FDA before they can begin their activity after notifying the agency?
VERBATIM ANSWER: Yes, yes you do. We have a database of distributors some of which have known issues that we don't necessarily immediately approve. So it's important to run that distributor list by us and get our approval before doing that.
SPEAKER QUESTION: Mark Swanson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA approval for distributors, CLIA-certified labs, EUA notifications
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Does the FDA add authorized distributors and labs to its listings?
CLARIFIED ANSWER: The FDA may require validation review before approving the addition of CLIA-certified labs or authorized distributors. The need depends on the original EUA's authorization language, and specific cases should be discussed with the FDA lead reviewer.
VERBATIM QUESTION: Does the FDA add authorized distributors and labs to its listings?
VERBATIM ANSWER: So if you're adding labs to an LDT sort of authorization, frequently we do want to review the validation for that. We have seen issues and have been unable to add labs. But it all depends on the original authorization and the original authorization language. For instance, some have been not needed. So others have been needed. So I think that's a specific enough a question depending on the language in the authorization to go back to your lead reviewer on that application for the greatest specificity of an answer.
SPEAKER QUESTION: Mark Swanson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: authorized distributors, CLIA-certified labs, EUA process
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: Is notification required for additional CLIA-certified labs and must they wait for response authorization before starting activity?
CLARIFIED ANSWER: FDA often reviews validation for adding labs under an LDT authorization, but the need for agency approval depends on the original authorization language. Consult the lead reviewer for specific guidance.
VERBATIM QUESTION: Is notification required for additional CLIA-certified labs and must they wait for response authorization before starting activity?
VERBATIM ANSWER: So if you're adding labs to an LDT sort of authorization, frequently we do want to review the validation for that. We have seen issues and have been unable to add labs. But it all depends on the original authorization and the original authorization language. For instance, some have been not needed. So others have been needed. So I think that's a specific enough a question depending on the language in the authorization to go back to your lead reviewer on that application for the greatest specificity of an answer.
SPEAKER QUESTION: Mark Swanson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CLIA-certified labs, LDT authorization, FDA notification requirements
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Does FDA review the validation of labs being added to an LDT authorization?
CLARIFIED ANSWER: FDA often reviews the validation when adding labs to an LDT authorization, although the need for review depends on the original authorization and its specific language.
VERBATIM QUESTION: Does FDA review the validation of labs being added to an LDT authorization?
VERBATIM ANSWER: So if you're adding labs to an LDT sort of authorization, frequently we do want to review the validation for that. We have seen issues and have been unable to add labs. But it all depends on the original authorization and the original authorization language. For instance, some have been not needed. So others have been needed. So I think that's a specific enough a question depending on the language in the authorization to go back to your lead reviewer on that application for the greatest specificity of an answer.
SPEAKER QUESTION: Mark Swanson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: LDT authorization, validation reviews, CLIA-certified labs
REVIEW FLAG: False


#### 11. FDA Prioritization of Quantitative and Neutralizing Antibody Tests

QA Block 11-1
CLARIFIED QUESTION: Is the FDA not planning to review any lab-based high volume, high throughput, high capacity, qualitative serology tests?
CLARIFIED ANSWER: The FDA prioritizes tests that can quantitate antibody levels or detect neutralizing antibodies, as these are important for assessing correlates of immunity and linking results to standardized units. Fully qualitative tests are not the current focus.
VERBATIM QUESTION: Is the FDA not planning to review any lab-based high volume, high throughput, high capacity, qualitative serology tests?
VERBATIM ANSWER: At this point, the priority is for high volume point-of-care or central lab tests that can quantitate the level of antibody or detect neutralizing antibody. As the science has developed here on serology, we feel that if there's going to be an expansion of use of serology, it's going to depend on whether you can have an assay that detects neutralizing antibody. Or can fully quantitate, so that if there is an immune correlate that we can put it into international units. Because many of the studies that are ongoing are not using an EUA authorized tests or in this manner that are fully quantitative. So we need to have a way to link those study results to assays without requiring the assays to go ahead and do the big clinical validation for correlates to immunity. So this is how we're trying to be least burdensome in applying any known correlates of immunity to serology tests.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA priorities for serology tests, qualitative vs quantitative serology, correlates of immunity
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: What are the priority criteria for point-of-care or central lab tests related to serology?
CLARIFIED ANSWER: The FDA prioritizes high-volume point-of-care or central lab serology tests that can either quantitate antibody levels or detect neutralizing antibodies. This allows for potential immune correlates to be connected without extensive clinical validation, facilitating expanded serology use.
VERBATIM QUESTION: What are the priority criteria for point-of-care or central lab tests related to serology?
VERBATIM ANSWER: At this point, the priority is for high volume point-of-care or central lab tests that can quantitate the level of antibody or detect neutralizing antibody. As the science has developed here on serology, we feel that if there's going to be an expansion of use of serology, it's going to depend on whether you can have an assay that detects neutralizing antibody. Or can fully quantitate, so that if there is an immune correlate that we can put it into international units. Because many of the studies that are ongoing are not using an EUA authorized tests or in this manner that are fully quantitative. So we need to have a way to link those study results to assays without requiring the assays to go ahead and do the big clinical validation for correlates to immunity. So this is how we're trying to be least burdensome in applying any known correlates of immunity to serology tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology test priorities, point-of-care tests, immune correlates
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Does the FDA require detection of neutralizing antibodies for new serology test approvals?
CLARIFIED ANSWER: The FDA prioritizes serology tests that can quantitate antibodies or detect neutralizing antibodies, as such assays are considered crucial for expanded use and application of serology.
VERBATIM QUESTION: Does the FDA require detection of neutralizing antibodies for new serology test approvals?
VERBATIM ANSWER: At this point, the priority is for high volume point-of-care or central lab tests that can quantitate the level of antibody or detect neutralizing antibody. As the science has developed here on serology, we feel that if there's going to be an expansion of use of serology, it's going to depend on whether you can have an assay that detects neutralizing antibody. Or can fully quantitate, so that if there is an immune correlate that we can put it into international units.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA serology test priorities, neutralizing antibodies, quantitative assays
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: How does the FDA define fully quantitative assays in the context of serology testing?
CLARIFIED ANSWER: Fully quantitative assays in serology testing are those that can detect neutralizing antibodies and express results in international units, enabling linkage to immune correlates without requiring extensive clinical validation.
VERBATIM QUESTION: How does the FDA define fully quantitative assays in the context of serology testing?
VERBATIM ANSWER: As the science has developed here on serology, we feel that if there's going to be an expansion of use of serology, it's going to depend on whether you can have an assay that detects neutralizing antibody. Or can fully quantitate, so that if there is an immune correlate that we can put it into international units. Because many of the studies that are ongoing are not using an EUA authorized tests or in this manner that are fully quantitative. So we need to have a way to link those study results to assays without requiring the assays to go ahead and do the big clinical validation for correlates to immunity.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Quantitative assays, Serology testing, Neutralizing antibodies
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Are there simplified validation requirements for assays intending to integrate immune correlate data without prior clinical validation?
CLARIFIED ANSWER: FDA seeks to reduce burdens for assays applying immune correlates by not requiring extensive clinical validation, focusing instead on assays that quantify or detect neutralizing antibodies.
VERBATIM QUESTION: Are there simplified validation requirements for assays intending to integrate immune correlate data without prior clinical validation?
VERBATIM ANSWER: At this point, the priority is for high volume point-of-care or central lab tests that can quantitate the level of antibody or detect neutralizing antibody. As the science has developed here on serology, we feel that if there's going to be an expansion of use of serology, it's going to depend on whether you can have an assay that detects neutralizing antibody. Or can fully quantitate, so that if there is an immune correlate that we can put it into international units. Because many of the studies that are ongoing are not using an EUA authorized tests or in this manner that are fully quantitative. So we need to have a way to link those study results to assays without requiring the assays to go ahead and do the big clinical validation for correlates to immunity. So this is how we're trying to be least burdensome in applying any known correlates of immunity to serology tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology assays, Immune correlates, Simplified validation
REVIEW FLAG: False


#### 12. Antigen Test Enrollment and Performance Study Clarifications

QA Block 12-1
CLARIFIED QUESTION: What is the patient enrollment requirement for the clinical performance study of antigen over-the-counter tests, specifically regarding the number of symptomatic and asymptomatic participants?
CLARIFIED ANSWER: FDA continues to require 30 symptomatic participants for the clinical performance study. For asymptomatic testing, if pursuing a single-use screening test, 10 asymptomatic samples with demonstrated performance are needed before authorization, and an additional 10 to reach a total of 20.
VERBATIM QUESTION: What is the patient enrollment requirement for the clinical performance study of antigen over-the-counter tests, specifically regarding the number of symptomatic and asymptomatic participants?
VERBATIM ANSWER: I thought it was still 30 symptomatics and that you could go the serial testing route for asymptomatic screening without any asymptomatic patients. But premarket, if you wanted a single use screening test, we do want to see adequate performance on 10 asymptomatic samples prior to authorization. And then for subsequently, an additional 10 or whatever is needed to bring it up to the total of 20.
SPEAKER QUESTION: Meijie Tang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: patient enrollment, clinical study requirements, antigen test performance
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Is it correct that 30 symptomatic participants are still the minimum required for the clinical performance study, with or without an asymptomatic claim?
CLARIFIED ANSWER: Yes, 30 symptomatic participants are likely still required, but it is recommended to follow up with FDA via email to confirm details based on the specific claim being sought.
VERBATIM QUESTION: Is it correct that 30 symptomatic participants are still the minimum required for the clinical performance study, with or without an asymptomatic claim?
VERBATIM ANSWER: You know, I think I would say yes. But I would say this is a very important study detail for you. And it might be best to follow up with an email so we're just we're absolutely sure what kind of claim that you're going for. If it's single use symptomatic plus a serial asymptomatic claim, if that is the case, then just let us know, and then we can get back you with the email with exactly what numbers we're expecting from that.
SPEAKER QUESTION: Meijie Tang
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: clinical performance study, symptomatic participant requirements, asymptomatic claims
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: For a single use symptomatic test plus a serial asymptomatic claim, what specific numbers are expected for the clinical performance study?
CLARIFIED ANSWER: FDA recommends following up via email to confirm the specific numbers expected for a single-use symptomatic plus serial asymptomatic claim.
VERBATIM QUESTION: For a single use symptomatic test plus a serial asymptomatic claim, what specific numbers are expected for the clinical performance study?
VERBATIM ANSWER: If it's single use symptomatic plus a serial asymptomatic claim, if that is the case, then just let us know, and then we can get back you with the email with exactly what numbers we're expecting from that.
SPEAKER QUESTION: Meijie Tang
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: single-use symptomatic testing, serial asymptomatic claim, clinical performance study
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: What are the specific performance validation requirements for asymptomatic testing claims, both premarket and postmarket?
CLARIFIED ANSWER: FDA requires 30 symptomatic samples for validation, but for asymptomatic claims, if it's a single-use screening test, 10 asymptomatic samples must demonstrate adequate premarket performance, with an additional 10 needed later to reach 20 in total.
VERBATIM QUESTION: What are the specific performance validation requirements for asymptomatic testing claims, both premarket and postmarket?
VERBATIM ANSWER: I thought it was still 30 symptomatics and that you could go the serial testing route for asymptomatic screening without any asymptomatic patients. But premarket, if you wanted a single use screening test, we do want to see adequate performance on 10 asymptomatic samples prior to authorization. And then for subsequently, an additional 10 or whatever is needed to bring it up to the total of 20.
SPEAKER QUESTION: Meijie Tang
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: performance validation, asymptomatic testing, premarket and postmarket requirements
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: Under what circumstances can the FDA deviate from the standard validation pathway for clinical performance studies?
CLARIFIED ANSWER: The FDA may deviate from the standard validation pathway when additional information is available for specific tests.
VERBATIM QUESTION: Under what circumstances can the FDA deviate from the standard validation pathway for clinical performance studies?
VERBATIM ANSWER: In some cases, we have-- because there's other information available on particular tests --we have deviated from that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: FDA validation deviations, clinical performance studies
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: How many asymptomatic samples are needed for premarket authorization of a single-use test with asymptomatic claims?
CLARIFIED ANSWER: For premarket authorization of a single-use screening test with asymptomatic claims, the FDA requires adequate performance on 10 asymptomatic samples initially, with an additional 10 later to total 20.
VERBATIM QUESTION: How many asymptomatic samples are needed for premarket authorization of a single-use test with asymptomatic claims?
VERBATIM ANSWER: But premarket, if you wanted a single use screening test, we do want to see adequate performance on 10 asymptomatic samples prior to authorization. And then for subsequently, an additional 10 or whatever is needed to bring it up to the total of 20.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: premarket authorization, asymptomatic sampling, single-use tests
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: What is the process for obtaining FDA clarification on specific study requirements for combination testing claims (e.g., single use symptomatic and serial asymptomatic claims)?
CLARIFIED ANSWER: FDA recommends following up with an email to clarify the exact claim type, and they will provide the specific study requirements, including sample numbers, in response.
VERBATIM QUESTION: What is the process for obtaining FDA clarification on specific study requirements for combination testing claims (e.g., single use symptomatic and serial asymptomatic claims)?
VERBATIM ANSWER: You know, I think I would say yes. But I would say this is a very important study detail for you. And it might be best to follow up with an email so we're just we're absolutely sure what kind of claim that you're going for. If it's single use symptomatic plus a serial asymptomatic claim, if that is the case, then just let us know, and then we can get back you with the email with exactly what numbers we're expecting from that.
SPEAKER QUESTION: Meijie Tang
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: FDA clarification process, Combination testing claims, Study requirements
REVIEW FLAG: False


#### 13. EUA Primer Transition and Verification Paperwork Requirements

QA Block 13-1
CLARIFIED QUESTION: Do we need to submit any paperwork for verification of performance to the CDC single primer set by Friday if we use the CDC panel while it was under EUA prior to November 15th and have since ordered primers from a different vendor where it's no longer labeled EUA?
CLARIFIED ANSWER: The FDA advised that the primers you are now using are Research Use Only (RUO) and lack quality control by the CDC, unlike the EUA-authorized primers. You should immediately email the templates box so the FDA can help address the situation offline.
VERBATIM QUESTION: If we use the CDC panel while it was under EUA prior to November 15th and then we've ordered primers from a different vendor where it's no longer labeled EUA, do we need to submit any paperwork for verification on the performance to the CDC single primer set by Friday?
VERBATIM ANSWER: Yeah they're RUO and they're not quality. The previous primers that were EUA authorized were quality controlled by the CDC. They would do a QC check on every batch. And can you immediately send an email to the templates box today? And we'll sort this out offline for you, Debs. OK?
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA verification, CDC panel primers, Quality control
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What is the quality of RUO primers compared to EUA-authorized primers?
CLARIFIED ANSWER: RUO primers are not considered high quality, unlike EUA-authorized primers, which are quality controlled by the CDC with a QC check on every batch.
VERBATIM QUESTION: What is the quality of RUO primers compared to EUA-authorized primers?
VERBATIM ANSWER: Yeah they're RUO and they're not quality. The previous primers that were EUA authorized were quality controlled by the CDC. They would do a QC check on every batch.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO primers, EUA quality control, CDC validation
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: How does the lack of quality control checks for RUO primers impact compliance or authorization?
CLARIFIED ANSWER: RUO primers lack quality control checks, unlike EUA-authorized primers which were quality controlled by the CDC for each batch.
VERBATIM QUESTION: How does the lack of quality control checks for RUO primers impact compliance or authorization?
VERBATIM ANSWER: Yeah they're RUO and they're not quality. The previous primers that were EUA authorized were quality controlled by the CDC. They would do a QC check on every batch. And can you immediately send an email to the templates box today? And we'll sort this out offline for you, Debs. OK?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RUO vs EUA primers, quality control checks, authorization impact
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: Who should be contacted for issues related to reagents or primer authorization changes?
CLARIFIED ANSWER: FDA advises emailing the templates box immediately for issues related to reagents or primer authorization changes.
VERBATIM QUESTION: Who should be contacted for issues related to reagents or primer authorization changes?
VERBATIM ANSWER: Can you immediately send an email to the templates box today? And we'll sort this out offline for you, Debs. OK?
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reagent authorization, primer changes, FDA templates email
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What is the process for resolving questions about reagent sourcing when switching from EUA to RUO materials?
CLARIFIED ANSWER: FDA recommends sending an email to the templates box to address reagent sourcing questions when switching from EUA to RUO materials, as RUO primers are not quality controlled by CDC like the EUA ones were.
VERBATIM QUESTION: What is the process for resolving questions about reagent sourcing when switching from EUA to RUO materials?
VERBATIM ANSWER: Yeah they're RUO and they're not quality. The previous primers that were EUA authorized were quality controlled by the CDC. They would do a QC check on every batch. And can you immediately send an email to the templates box today? And we'll sort this out offline for you, Debs. OK?
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: reagent sourcing, EUA to RUO transition, primer quality control
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What steps are necessary to ensure continued compliance and authorization when reagents labeled under EUA are no longer available under that designation?
CLARIFIED ANSWER: FDA recommends reaching out via email to the templates box for assistance when transitioning from reagents previously labeled under EUA to those without such authorization to maintain compliance and market availability.
VERBATIM QUESTION: What steps are necessary to ensure continued compliance and authorization when reagents labeled under EUA are no longer available under that designation?
VERBATIM ANSWER: Yeah they're RUO and they're not quality. The previous primers that were EUA authorized were quality controlled by the CDC. They would do a QC check on every batch. And can you immediately send an email to the templates box today? And we'll sort this out offline for you, Debs. OK?
SPEAKER QUESTION: Debs Payne
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA reagent compliance, Quality control, Regulatory process
REVIEW FLAG: False


#### 14. Updating Antigen Test Labels for Omicron Detection

QA Block 14-1
CLARIFIED QUESTION: How do you recommend manufacturers that are conducting omicron variant studies and getting results from the NIH to update their package inserts?
CLARIFIED ANSWER: Manufacturers with NIH omicron testing data on their antigen tests should request an EUA supplement to update their package insert. The FDA can assist with ensuring the Instructions for Use reflect omicron detection.
VERBATIM QUESTION: OK with the new omicron variant data that Siemens was able to put into their package insert, how do you recommend other manufacturers that are now conducting their studies and getting their results back from the NIH, can they just update their package inserts? Or do they have to send that into the FDA?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: omicron variant testing, package insert updates, NIH data usage
REVIEW FLAG: False

QA Block 14-2
CLARIFIED QUESTION: Do manufacturers have to send updated package inserts to the FDA for approval?
CLARIFIED ANSWER: Manufacturers must submit a supplement request to the FDA to update package inserts with approved NIH data, and the FDA will assist in updating the labeling.
VERBATIM QUESTION: Do manufacturers have to send updated package inserts to the FDA for approval?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Updating package inserts, Manufacturer requirements, COVID-19 omicron data
REVIEW FLAG: False

QA Block 14-3
CLARIFIED QUESTION: What is the process for FDA updating antigen test labels to reflect performance against the omicron variant?
CLARIFIED ANSWER: The FDA updates antigen test labels to include NIH data showing omicron detection. Developers can request label updates through a supplement to expedite the process.
VERBATIM QUESTION: What is the process for FDA updating antigen test labels to reflect performance against the omicron variant?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test label updates, Omicron variant, NIH data use
REVIEW FLAG: False

QA Block 14-4
CLARIFIED QUESTION: Can developers expedite the label update process for omicron detection through a supplement request?
CLARIFIED ANSWER: Developers can expedite the label update process for omicron detection by submitting a supplement request to the FDA with NIH data, and the FDA will assist in updating the labeling.
VERBATIM QUESTION: Can developers expedite the label update process for omicron detection through a supplement request?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: label updates, omicron detection, supplement request
REVIEW FLAG: False

QA Block 14-5
CLARIFIED QUESTION: What steps should be taken to update Instructions for Use (IFU) with omicron variant data?
CLARIFIED ANSWER: Manufacturers should request an IFU update in a supplement if they have NIH omicron testing data. The FDA will work with them on necessary updates to reflect omicron detection.
VERBATIM QUESTION: What steps should be taken to update Instructions for Use (IFU) with omicron variant data?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: IFU updates, omicron variant testing, NIH data usage
REVIEW FLAG: False

QA Block 14-6
CLARIFIED QUESTION: Does pre-authorization status of a test affect how FDA incorporates NIH omicron data into the labeling?
CLARIFIED ANSWER: The FDA incorporates NIH omicron data into labeling differently for tests that are pre-authorization by working with RADx to include the data, while also updating labels for authorized tests. Developers can request expedited updates.
VERBATIM QUESTION: Does pre-authorization status of a test affect how FDA incorporates NIH omicron data into the labeling?
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: Menzelk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-authorization tests, NIH omicron data, test labeling process
REVIEW FLAG: False

QA Block 14-7
CLARIFIED QUESTION: What role does RADx play in updating antigen test labels with data related to omicron variants?
CLARIFIED ANSWER: FDA works with RADx to update antigen test labels based on NIH omicron testing. Developers can submit NIH data in a supplement to expedite label updates for omicron performance.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: So if the NIH has done their omicron testing on an antigen test, either an EUA authorized test or one that's going through one of the RADx or ITAP process, if it's pre-authorization we're working with RADx to put that into the labeling that we did for Siemens. But we will go through the antigen tests and update those labels. So if a particular developer, you, wants to come in and speed up that label update showing that you are detecting omicron, I think that's an important element due to the question about omicron performance. And we want to work with you on that. So if you have NIH data you can just make that request in a supplement, and we will work with you to get the IFU updated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: RADx role in label updates, Omicron variant, Antigen test labeling
REVIEW FLAG: False


#### 15. FDAâs Stance on Over-the-Counter Serology Tests

QA Block 15-1
CLARIFIED QUESTION: Will the FDA be accepting and reviewing over-the-counter serology point-of-care test submissions?
CLARIFIED ANSWER: The FDA is not prioritizing the review of over-the-counter serology point-of-care test submissions.
VERBATIM QUESTION: Will the FDA be accepting and reviewing over-the-counter serology point-of-care test submissions?
VERBATIM ANSWER: So Toby said what we were prioritizing and we are not prioritizing over-the-counter serology tests.
SPEAKER QUESTION: Sunil Hazaray
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA priorities, Over-the-counter serology tests, Diagnostics review
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: Where can the recording and transcript of this Town Hall be accessed?
CLARIFIED ANSWER: The recording and transcript of the Town Hall can be accessed at www.fda.gov/training/cdrhlearn under the subsection titled 'Coronavirus COVID-19 Test Development and Validation Virtual Town Hall Series.'
VERBATIM QUESTION: Where can the recording and transcript of this Town Hall be accessed?
VERBATIM ANSWER: Today's program and transcript will be made available at CDRH Learn. Please visit CDRH Learn at www.fda.gov/training/cdrhlearn. You will find the recording and transcript in the subsection titled Coronavirus COVID-19 Test Development and Validation Virtual Town Hall Series.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: Town Hall recording, transcript access
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: What is the email address to contact the FDA regarding additional COVID-19 IVD-related questions?
CLARIFIED ANSWER: You can contact the FDA regarding additional COVID-19 IVD-related questions by emailing CDRH-EUAÂ­ Templates@fda.hhs.gov.
VERBATIM QUESTION: What is the email address to contact the FDA regarding additional COVID-19 IVD-related questions?
VERBATIM ANSWER: For additional questions about today's Town Hall and COVID-19 IVD topics in general, please email CDRH-EUAÂ­ Templates@fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: FDA contact information, COVID-19 IVD inquiries
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: When is the next IVD Town Hall scheduled?
CLARIFIED ANSWER: The next IVD Town Hall is scheduled for Wednesday, January 26, 2022.
VERBATIM QUESTION: When is the next IVD Town Hall scheduled?
VERBATIM ANSWER: Also please remember to join us for the next IVD Town Hall scheduled for Wednesday January 26, 2022.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: IVD Town Hall schedule
REVIEW FLAG: False

### removed qa blocks
QA Block 1-3
CLARIFIED QUESTION: Can FDA clarify the types of modifications that can be made by a laboratory to an authorized COVID-19 molecular diagnostic test after November 15, 2021?
CLARIFIED ANSWER: Laboratories can modify authorized COVID-19 molecular diagnostic tests by introducing a new specimen type, provided this type is already authorized for another test of the same technology and the lab validates the modification. Other changes require FDA notification or a new/amended EUA.
VERBATIM QUESTION: Can FDA clarify the types of modifications that can be made by a laboratory to an authorized COVID-19 molecular diagnostic test after November 15, 2021?
VERBATIM ANSWER: Laboratories may make certain modifications to an authorized COVID-19 molecular diagnostic test, like using a new specimen type, but only if that specimen type has been previously authorized for another test of the same technology. The laboratory must also validate the test for use with the new specimen type. As outlined in the updated guidance, any modifications that do not fall under these conditions would require notification to the FDA or a new or amended EUA.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: laboratory test modifications, post-November 2021 policies, FDA authorization requirements
REVIEW FLAG: False

QA Block 4-1
CLARIFIED QUESTION: Is FDA considering priority review for over-the-counter and point-of-care serology tests?
CLARIFIED ANSWER: FDA will prioritize review of lab-based and point-of-care serology tests that are high throughput and measure antibody titers or detect neutralizing antibodies, particularly from developers capable of scaling up manufacturing after authorization.
VERBATIM QUESTION: Is FDA considering priority review for over-the-counter and point-of-care serology tests?
VERBATIM ANSWER: So as stated in the revised guidance issued November 15, we do intend to prioritize review of lab-based and point-of-care serology tests that are high throughput, intended for the quantitative measurement of antibody titers, or the quantitative detection of neutralizing antibodies from developers who have indicated the ability to scale up manufacturing capacity shortly after authorization.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: priority review, serology tests, FDA guidance
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: How many symptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
CLARIFIED ANSWER: The FDA generally expects at least 20 symptomatic individuals and 10 asymptomatic individuals for over-the-counter test authorization.
VERBATIM QUESTION: How many symptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
VERBATIM ANSWER: We generally would expect at least 20 symptomatic individuals, and 10 asymptomatic individuals at the time of authorization.
SPEAKER QUESTION: Joseph Tartal (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: symptomatic individuals, over-the-counter test, authorization criteria
REVIEW FLAG: False

QA Block 9-1
CLARIFIED QUESTION: Must a developer have an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?
CLARIFIED ANSWER: The FDA prefers usability studies to be conducted as closely as possible to the actual way the test will be performed, depending on the intended final product and user interaction.
VERBATIM QUESTION: Must a developer have an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?
VERBATIM ANSWER: So we generally want to see the usability study performed as close as possible to how the test will be performed. So it really depends on what you're intending to use as a final product and how a user will interface with it. We would want to see the usability study address it that way.
SPEAKER QUESTION: Karl Enters
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: usability study, OTC tests, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Do you need to wait for FDA response when adding new distributors for a test?
CLARIFIED ANSWER: Yes, FDA approval is required before adding new distributors for a test. The distributor list must be submitted for review and approval due to potential issues.
VERBATIM QUESTION: Do you need to wait for FDA response when adding new distributors for a test?
VERBATIM ANSWER: Yes, yes you do. We have a database of distributors some of which have known issues that we don't necessarily immediately approve. So it's important to run that distributor list by us and get our approval before doing that.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA response for adding distributors, Distributor approval, Regulatory process
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-05 05:32:50 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 15
##### Explicit Questions Extraction
QE 1-1: Would a premarket submission for over-the-counter COVID-19 tests be submitted as a 510(k), or would this be a de novo?
QE 1-2: Can FDA clarify whether modifications made by a laboratory to an emergency use authorized COVID-19 diagnostic test prior to November 15, 2021, to add new specimen types can continue to be used without FDA authorization?
QE 1-3: Can FDA clarify the types of modifications that can be made by a laboratory to an authorized COVID-19 molecular diagnostic test after November 15, 2021?

##### Implicit Questions Extraction
QI 1-1: What is the process for submitting validation data for laboratories developing an LDT and needing EUA authorization?
QI 1-2: Does the FDA require a specific test volume threshold for LDTs seeking EUA authorization?
QI 1-3: What are the acceptable methods for validating diagnostic tests for Omicron-specific performance on antigen tests?
QI 1-4: For new submissions involving omicron, what types of clinical data are recommended by the FDA to demonstrate test performance?
QI 1-5: How does the FDA view the use of oropharyngeal or throat swabs in authorized diagnostic tests, especially those used by consumers at home?
QI 1-6: What kind of data should accompany submissions involving saliva or throat swabs to demonstrate their effectiveness as sample types for COVID-19 tests?
QI 1-7: Are there recommended safety measures or data points to address potential risks associated with throat swab self-collection?
QI 1-8: Can a genotyping test for SARS-CoV-2 variants meet diagnostic validation requirements by incorporating data from archived samples or genomic sequencing?
QI 1-9: What validation plans are recommended for developers implementing a genotyping claim in sequencing-based assays?
QI 1-10: What criteria must be satisfied to make pre-authorized updates in genotyping test protocols without FDA pre-review?

#### Section 2 of 15
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 2-1: What are FDA's expectations for EUA submissions when a modification changes the indication for use of a test?
QI 2-2: What does the FDA consider a high complexity CLIA-certified laboratory in the context of modified tests?
QI 2-3: Are laboratories allowed to state or imply FDA authorization for modified tests offered under the FDA modifications policy?
QI 2-4: What types of modifications to an EUA-authorized test do not require a new EUA, according to the FDA?
QI 2-5: Does changing PCR primers or probes require a new or amended EUA?
QI 2-6: Are modifications involving additional specimen types or patient populations, such as asymptomatic individuals, covered under the FDA modifications policy?
QI 2-7: What recommendations for transparency does the FDA provide for laboratories offering tests under the modifications policy?

#### Section 3 of 15
##### Explicit Questions Extraction
QE 3-1: Are usability and clinical studies required to support the addition of a mobile app for an over-the-counter antigen test?

##### Implicit Questions Extraction
QI 3-1: What does the FDA mean by assessing the actual use environment in usability studies?
QI 3-2: Should the electronic instructions and result interpretation of the mobile app be part of the usability study?
QI 3-3: How should developers handle usability testing for the entire workflow of a mobile app in an over-the-counter antigen test?

#### Section 4 of 15
##### Explicit Questions Extraction
QE 4-1: Is FDA considering priority review for over-the-counter and point-of-care serology tests?

##### Implicit Questions Extraction
QI 4-1: What criteria does the FDA use to prioritize review of lab-based and point-of-care serology tests?
QI 4-2: Does the ability to scale up manufacturing capacity influence the FDA's prioritization decisions for serology test reviews?
QI 4-3: Are there specific requirements for quantitative measurement of antibody titers when reviewing serology tests?
QI 4-4: What are the prioritization considerations for tests detecting neutralizing antibodies?

#### Section 5 of 15
##### Explicit Questions Extraction
QE 5-1: Can FDA clarify the clinical study patient enrollment recommendations to support an over-the-counter test?

##### Implicit Questions Extraction
QI 5-1: What are the requirements for separating and combining symptomatic and asymptomatic data for over-the-counter tests?
QI 5-2: How many symptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
QI 5-3: How many asymptomatic individuals are generally expected in a clinical study for over-the-counter test authorization?
QI 5-4: What is the FDA definition of 'asymptomatic individuals' for clinical studies?
QI 5-5: Should individuals with known COVID-19 exposure be excluded from the asymptomatic category during clinical studies?
QI 5-6: What documentation is required to confirm enrolled individuals meet the asymptomatic criteria for the clinical study?
QI 5-7: What specific clinical study information should be submitted with the EUA request for over-the-counter tests?
QI 5-8: What details must be included for symptomatic individuals in the clinical validation study?
QI 5-9: How should performance data be stratified for clinical validation of an over-the-counter test?

#### Section 6 of 15
##### Explicit Questions Extraction
QE 6-1: What is FDA's position on serial antigen testing once per week?

##### Implicit Questions Extraction
QI 6-1: What type of performance data is required to support a proposal for extending the serial testing interval to weekly for antigen tests?
QI 6-2: What process should developers follow to submit a proposed study design for extending the serial testing interval for antigen tests?
QI 6-3: What are the specific authorized instructions for use around repeat testing within indicated time frames for antigen tests?
QI 6-4: When submitting new data, do developers need to align with current authorization timelines for serial testing (e.g., three days with 24-48 hours between tests)?

#### Section 7 of 15
##### Explicit Questions Extraction
QE 7-1: Do you have any clarification on how the transition from the emergency use authorization to regular use will be implemented?

##### Implicit Questions Extraction
QI 7-1: What specific elements should be addressed in comments submitted to the draft Transition Plan guidance docket?
QI 7-2: What measures will the FDA use to ensure COVID-19 tests remain accurate and reliable during the post-emergency transition?
QI 7-3: Are there specific instructions on how to submit a CLIA validation to the FDA for LDTs validated prior to November 15, 2021?
QI 7-4: How will the FDA handle issues or concerns with LDTs submitted under the guidance for the January 14 deadline?
QI 7-5: Is there a requirement to pause LDT testing during FDA review after the submission for the January 14 deadline?

#### Section 8 of 15
##### Explicit Questions Extraction
QE 8-1: Would the FDA consider saliva as a comparator test for COVID-19 diagnostics?
QE 8-2: Can both NP and saliva samples be used for RT-PCR and compared with antigen test results?

##### Implicit Questions Extraction
QI 8-1: What considerations should be taken into account for handling discordant test results involving antigen tests and NP swabs?
QI 8-2: How can discordant analysis inform positive percent agreement (PPA) or negative percent agreement (NPA) during validation?
QI 8-3: Is it acceptable to focus on properly conducted discordant samples for performance analysis, and how should this be presented in performance tables?
QI 8-4: Can a saliva test confirmed as SARS-CoV-2 positive be used as evidence to address discordances observed with NP swabs?
QI 8-5: What details should be included in a Pre-EUA submission about discordant resolution design and study design for COVID-19 diagnostics?

#### Section 9 of 15
##### Explicit Questions Extraction
QE 9-1: Must a developer have an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?
QE 9-2: Can a developer use a hybrid model with screenshots and a keypad instead of an actual device to conduct a usability study for an over-the-counter COVID-19 test using an app?

##### Implicit Questions Extraction

#### Section 10 of 15
##### Explicit Questions Extraction
QE 10-1: Do distributors and labs have to wait for a response from the FDA before they can begin their activity after notifying the agency?
QE 10-2: Does the FDA add authorized distributors and labs to its listings?
QE 10-3: Do you need to wait for FDA response when adding new distributors for a test?
QE 10-4: Is notification required for additional CLIA-certified labs and must they wait for response authorization before starting activity?
QE 10-5: Does FDA review the validation of labs being added to an LDT authorization?

##### Implicit Questions Extraction

#### Section 11 of 15
##### Explicit Questions Extraction
QE 11-1: Is the FDA not planning to review any lab-based high volume, high throughput, high capacity, qualitative serology tests?

##### Implicit Questions Extraction
QI 11-1: What are the priority criteria for point-of-care or central lab tests related to serology?
QI 11-2: Does the FDA require detection of neutralizing antibodies for new serology test approvals?
QI 11-3: How does the FDA define fully quantitative assays in the context of serology testing?
QI 11-4: Are there simplified validation requirements for assays intending to integrate immune correlate data without prior clinical validation?

#### Section 12 of 15
##### Explicit Questions Extraction
QE 12-1: What is the patient enrollment requirement for the clinical performance study of antigen over-the-counter tests, specifically regarding the number of symptomatic and asymptomatic participants?
QE 12-2: Is it correct that 30 symptomatic participants are still the minimum required for the clinical performance study, with or without an asymptomatic claim?
QE 12-3: For a single use symptomatic test plus a serial asymptomatic claim, what specific numbers are expected for the clinical performance study?

##### Implicit Questions Extraction
QI 12-1: What are the specific performance validation requirements for asymptomatic testing claims, both premarket and postmarket?
QI 12-2: Under what circumstances can the FDA deviate from the standard validation pathway for clinical performance studies?
QI 12-3: How many asymptomatic samples are needed for premarket authorization of a single-use test with asymptomatic claims?
QI 12-4: What is the process for obtaining FDA clarification on specific study requirements for combination testing claims (e.g., single use symptomatic and serial asymptomatic claims)?

#### Section 13 of 15
##### Explicit Questions Extraction
QE 13-1: Do we need to submit any paperwork for verification of performance to the CDC single primer set by Friday if we use the CDC panel while it was under EUA prior to November 15th and have since ordered primers from a different vendor where it's no longer labeled EUA?

##### Implicit Questions Extraction
QI 13-1: What is the quality of RUO primers compared to EUA-authorized primers?
QI 13-2: How does the lack of quality control checks for RUO primers impact compliance or authorization?
QI 13-3: Who should be contacted for issues related to reagents or primer authorization changes?
QI 13-4: What is the process for resolving questions about reagent sourcing when switching from EUA to RUO materials?
QI 13-5: What steps are necessary to ensure continued compliance and authorization when reagents labeled under EUA are no longer available under that designation?

#### Section 14 of 15
##### Explicit Questions Extraction
QE 14-1: How do you recommend manufacturers that are conducting omicron variant studies and getting results from the NIH to update their package inserts?
QE 14-2: Do manufacturers have to send updated package inserts to the FDA for approval?

##### Implicit Questions Extraction
QI 14-1: What is the process for FDA updating antigen test labels to reflect performance against the omicron variant?
QI 14-2: Can developers expedite the label update process for omicron detection through a supplement request?
QI 14-3: What steps should be taken to update Instructions for Use (IFU) with omicron variant data?
QI 14-4: Does pre-authorization status of a test affect how FDA incorporates NIH omicron data into the labeling?
QI 14-5: What role does RADx play in updating antigen test labels with data related to omicron variants?

#### Section 15 of 15
##### Explicit Questions Extraction
QE 15-1: Will the FDA be accepting and reviewing over-the-counter serology point-of-care test submissions?

##### Implicit Questions Extraction
QI 15-1: Where can the recording and transcript of this Town Hall be accessed?
QI 15-2: What is the email address to contact the FDA regarding additional COVID-19 IVD-related questions?
QI 15-3: When is the next IVD Town Hall scheduled?
